Most Americans, who have private insurance, likely will not benefit immediately from efforts to lower prescription drug ...

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug ...

Trump administration inks pricing deals with 9 drugmakers to align U.S. drug prices with lowest global rates and boost domestic manufacturing.

Pharma companies have agreed to lower prices and invest in the U.S. in exchange for avoiding tariffs and benefits like faster drug reviews.

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, ...

Eli Lilly struck a deal with President Donald Trump, lowering the prices of its blockbuster weight loss drugs. In return, Lilly gains exemption from import tariffs and other benefits. 10 stocks we ...

The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday, Bloomberg News reported on Wednesday, citing people familiar with the ...

Bristol Myers (BMY) stock is in focus as the firm to offer its Pfizer (PFE)-partnered Eliquis, free to Medicaid as part of a U.S. pricing deal. Read more here.

The United States and the United Kingdom reached an agreement in principle on pharmaceutical pricing. The update comes as part of the U.S.–U.K. Economic Prosperity Deal (EPD), announced Dec. 1. The ...

The U.S. and the United Kingdom reached an agreement in principle to address pharmaceutical pricing disparities and secure investment under the U.S.-U.K. Economic Prosperity Deal. According to a Dec.